Is Retatrutide safe?
Trial data; no long-term safety
Gut effects were the most common side effects in every trial. These were nausea, diarrhea, vomiting and constipation. They were dose-related, and a lower starting dose reduced them. Heart rate rose with the dose. It peaked around 24 weeks at a few beats per minute above placebo and then declined. Other GLP-1 drugs do this too. But the glucagon part makes it a point to watch. In TRIUMPH-2, one in nine participants on the middle dose stopped because of side effects. There is no safety data beyond 80 weeks. There is none from unsupervised use of unregulated product. 247
Mostly nausea, vomiting, diarrhea and constipation. These were dose-related and eased with a lower starting dose. Heart rate rose by a few beats per minute in a dose-dependent way and then settled. Between 4 and 12 percent of participants in TRIUMPH-2 stopped because of side effects, against 5 percent on placebo. 24
Read the full Retatrutide page
More on Retatrutide
Citations
- StatPearls: GLP-1 receptor agonists ncbi.nlm.nih.gov
- Jastreboff 2023, N Engl J Med: triple-hormone-receptor agonist retatrutide for obesity, phase 2 trial pubmed.ncbi.nlm.nih.gov
- Sanyal 2024, Nat Med: retatrutide for metabolic dysfunction-associated steatotic liver disease, phase 2a substudy pubmed.ncbi.nlm.nih.gov
- Lancet 2026: TRIUMPH-2, retatrutide in adults with obesity and type 2 diabetes doi.org
- Eli Lilly Q2 2026 earnings release (SEC filing): retatrutide filing plans sec.gov
- FDA: concerns with unapproved GLP-1 drugs used for weight loss fda.gov
- Diabetes Obes Metab 2026: rationale and design of the TRIUMPH registrational trials pubmed.ncbi.nlm.nih.gov
- Eli Lilly press release, July 2026: TRIUMPH-2 and TRIUMPH-3 topline results biospace.com
- ClinicalTrials.gov: retatrutide trial listings clinicaltrials.gov
Reference information only, not medical advice. Drawn from the Retatrutide article, fact-checked against the cited sources. No dosing anywhere on this site.